Brand/Generic Settlements May Get Supreme Court Review In Tamoxifen Case
Executive Summary
The U.S. Supreme Court may take up the question of whether reverse settlements between brand and generic companies can violate antitrust laws
You may also be interested in...
Brand/Generic Settlements Bill May Pass, But Industry Sees Room To Maneuver
Recently introduced House legislation, while prohibiting "reverse" payments by brand pharmaceutical companies to delay generic launches, would be far more palatable to industry than its Senate counterpart because it confines potential violations to the Federal Trade Commission Act, according to Pfizer Corporate Counsel Dara Diomande
Brand/Generic Settlements Bill May Pass, But Industry Sees Room To Maneuver
Recently introduced House legislation, while prohibiting "reverse" payments by brand pharmaceutical companies to delay generic launches, would be far more palatable to industry than its Senate counterpart because it confines potential violations to the Federal Trade Commission Act, according to Pfizer Corporate Counsel Dara Diomande
Brand/Generic Settlements Bill Clears Senate Cmte., Awaits Day On The Floor
After relatively smooth sailing through the Senate Judiciary Committee, legislation to prohibit "reverse payments" in brand/generic settlements now faces the challenge of securing floor-time for consideration by the full chamber